MedDataX Logo

Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines

NCT ID: NCT00615992

Last Updated: 2016-02-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

754 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary goal of this post marketing surveillance (PMS) study is to document the efficacy of Tiotropium (Spiriva) to improve physical activity measured by a score that is recommended in national chronic obstructive pulmonary disease (COPD) guidelines for monitoring the course of the disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

NCT02172495

Pulmonary Disease, Chronic Obstructive
COMPLETED

Observational Non-interventional Study With Spiriva in Chronic Obstructive Pulmonary Disease Patients With Exercise-induced Dyspnoea

NCT00540163

Chronic Obstructive Pulmonary Disease
COMPLETED

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02172482

Pulmonary Disease, Chronic Obstructive
COMPLETED

Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients

NCT00157235

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE3

Tiotropium (Spiriva) Rehabilitation Study

NCT00274521

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tiotropium

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with suspected chronic obstructive pulmonary disease (COPD)
* 3 or more positive answers in COPD questionnaire
* Age over 40 years

Exclusion Criteria

* Patients with any conditions listed in special precautions, drug interactions, and contraindication of Spiriva in the summary of product characteristics
* Patient treated with Spiriva in the past year
* Patient with history of hypersensitivity to tiotropium bromide, atropine and/or its derivant, i.e. ipratropium, or any component of Spiriva Patient with known narrow-angle glaucoma Patient with known symptomatic prostatic hyperplasia and/or bladder-neck obstruction Patient with known moderate to severe renal impairment (i.e.,creatinine clearance\<=50ml/min) Pregnant or nursing women Patient with any significant disease other than COPD which would exclude him/her from participating in the study Patients with any conditions listed in special precautions, drug interactions, and contraindication of Spiriva in Austrian summary of product characteristics
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site

Admont, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Afritz Am See, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Altenmarkt, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Altmünster, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Bad Gleichenberg, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Bad Goisern am Hallstättersee, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Bad Hall, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Bad Häring, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Bleiburg, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Bludenz, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Brixlegg, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Drasenhofen, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Enns, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Fohnsdorf, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Gänserndorf, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Gmunden, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Grafenstein, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Graz, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Grünbach, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Gunskirchen, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Gutenstein, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Haid, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Hainburg/a.d. Donau, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Herzogenburg, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Hürm, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Innsbruck, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Jenbach, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Judenburg, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Kindberg, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Kirchberg Wechsel, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Klagenfurt, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Klein-Pöchlarn, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Knittelfeld, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Königswiesen, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Kuchl, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Langenrohr, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Lebring, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Leobersdorf, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Linz, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Lustenau, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Mank, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Mödling, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Neuberg/Mürz, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Neumarkt a.W., , Austria

Site Status

Boehringer Ingelheim Investigational Site

Neunkirchen, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Niederhollabrunn, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Oberschützen, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Ollersdorf, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Passail, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Peesen, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Pfarrkirchen bei Bad Hall, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Pichl bei Wels, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Pischeldorf, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Rattenberg, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Saint Johann, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Saint Stefan O Stainz, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Saint Veit Glan, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Salzburg, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Sankt Valentin, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Schwechat, , Austria

Site Status

Boehringer Ingelheim Investigational Site

St.Georgen/Judenburg 12, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Stainach, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Stasshof, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Traismauer, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Tulln, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Vöcklabruck, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Wallern an der Trattnach, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Weiz, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Weißtrach, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Wilhelmsburg, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Wolfsberg, , Austria

Site Status

Boehringer Ingelheim Investigational Site

Wolkersdorf, , Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

205.398

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00144326 COMPLETED PHASE3
Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice
NCT00624377 COMPLETED
Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients
NCT00274508 COMPLETED PHASE3
SPIRIVA in Ususal Care
NCT00274079 COMPLETED PHASE4
Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example
NCT01036763 COMPLETED
A Prescription-Event Monitoring (PEM) Study of Tiotropium
NCT02196194 COMPLETED
Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation
NCT02172521 COMPLETED
Tiotropium In Exercise
NCT00525512 COMPLETED PHASE4
Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities
NCT00621582 COMPLETED
Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.
NCT02172547 COMPLETED
Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory Disorders
NCT00274014 COMPLETED PHASE3
Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD
NCT00274053 COMPLETED PHASE3
Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema
NCT00570544 COMPLETED
Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
NCT01072396 COMPLETED PHASE4
Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).
NCT00239408 COMPLETED PHASE4
Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00239499 COMPLETED PHASE4
Special Survey Long-term Treatment With Tiotropium on COPD
NCT00638183 COMPLETED
Spiriva® Assessment of FEV1 (SAFE)
NCT00277264 COMPLETED PHASE3
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
NCT00144339 COMPLETED PHASE3
Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)
NCT00274027 COMPLETED PHASE3
Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease
NCT02177318 COMPLETED
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT03118765 COMPLETED PHASE2
Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT05986591 COMPLETED PHASE3
12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)
NCT00144196 COMPLETED PHASE4
Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD Patients
NCT00620516 COMPLETED